ANIP
ANI PHARMACEUTICALS INC
$81.66
-0.41%
$1.8B
No data for this timeframe.
Vol
Market Cap$1.8B
Cap SizeSmall Cap
Inst. Holders9 funds
Inst. Value$191.7M
Inst. Activity3 buys / 2 sells
Insider Activity0B / 20S
Insider Net $-$8.6M
Reddit Sentiment50° Neutral
SEC Reports9
Press Releases2
Recent Activity
May 14, 2026
SEC
A cluster of insider sales at ANI Pharmaceuticals, led by CEO Nikhil Lalwani selling $4.27M worth of shares, follows a s
CLUSTER — Impact 4/10
May 13, 2026
SEC
ANI Pharmaceuticals published an updated May 2026 investor presentation via an 8-K (Item 7.01), reiterating and raising
8-K — Impact 7/10
May 13, 2026
Insider
Cook Meredith sold 500 shares
SR. VP, GENERAL COUNSEL & SEC. @ $78.16 ($39.1K)
May 13, 2026
Insider
Walsh Patrick D sold 10,000 shares
Director @ $80.63 ($806.3K)
May 12, 2026
Insider
Gutwerg Ori sold 2,772 shares
SVP, GENERICS @ $79.50 ($220.4K)
May 8, 2026
SEC
ANI Pharmaceuticals reported Q1 2026 revenue of $237.5M (+20.5% YoY) and GAAP diluted EPS of $1.28, beating consensus es
8-K — Impact 8/10
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
181,151 shares ($14.3M)
Inst.
BANK OF AMERICA CORP — TRIM
45,704 shares ($3.6M)
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$109.88 (Jan 2026)
Current $81.66
Low $90.00
Median $110.00
High $124.00
8 analysts
$90.00
$124.00
Analyst Ratings
5Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 16, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Dec 9, 2025 | Barclays | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $2.00 ▼ -8.2% | $1.95 — $2.04 | 11% YoY | 7 |
| Next Q | $2.52 | $2.28 — $2.80 | 23% YoY | 7 |
| Current FY | $9.40 ▲ +3.6% | $9.19 — $9.60 | 19% YoY | 7 |
| Next FY | $10.61 | $9.48 — $13.06 | 13% YoY | 8 |
Latest Reports
NEUTRAL
CLUSTER
4/10
A cluster of insider sales at ANI Pharmaceuticals, led by CEO Nikhil Lalwani selling $4.27M worth of shares, follows a s
May 14, 2026
BULLISH
8-K
7/10
ANI Pharmaceuticals published an updated May 2026 investor presentation via an 8-K (Item 7.01), reiterating and raising
May 13, 2026
BULLISH
Press
7/10
ANI Pharmaceuticals announced FDA approval and immediate launch of Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg, t
Apr 8, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $103.0M | — |
| RENAISSANCE TECHNOLOGIES LLC | $24.8M | DOUBLED |
| MORGAN STANLEY | $22.2M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $19.9M | NEW |
| TWO SIGMA INVESTMENTS, LP | $14.3M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 13, 2026 | Cook Meredith | SELL | $39.1K |
| May 13, 2026 | Walsh Patrick | SELL | $806.3K |
| May 12, 2026 | Gutwerg Ori | SELL | $220.4K |
| May 12, 2026 | Rowland Thomas | SELL | $36.4K |
| May 11, 2026 | Lalwani Nikhil | SELL | $4.3M |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
9 institutional holders with $191.7M total value (2,428,470 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,305,068 | $103.0M | 53.7% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 314,402 | $24.8M | 12.9% | DOUBLED +112.6% |
| 3 | MORGAN STANLEY | 281,427 | $22.2M | 11.6% | TRIM -54.1% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 251,629 | $19.9M | 10.4% | NEW |
| 5 | TWO SIGMA INVESTMENTS, LP | 181,151 | $14.3M | 7.5% | DOUBLED +236.8% |
| 6 | BANK OF AMERICA CORP /DE/ | 45,704 | $3.6M | 1.9% | TRIM -65.0% |
| 7 | WELLS FARGO & COMPANY/MN | 29,647 | $2.3M | 1.2% | ADD +62.4% |
| 8 | FMR LLC | 9,857 | $778.1K | 0.4% | TRIM -71.9% |
| 9 | NORGES BANK | 9,585 | $756.6K | 0.4% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 53,783 | 181,151 | +236.8% | $14.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 130,732 | 45,704 | -65.0% | $3.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 18,253 | 29,647 | +62.4% | $2.3M | 2025-Q4 |
| FMR LLC | TRIM | 35,094 | 9,857 | -71.9% | $778.1K | 2025-Q4 |
| NORGES BANK | NEW | — | 9,585 | — | $756.6K | 2025-Q4 |
| UBS Group AG | ADD | 404,702 | 589,874 | +45.8% | $54.0M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 128,387 | 272,902 | +112.6% | $25.0M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 185,465 | 130,732 | -29.5% | $12.0M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 53,783 | — | $4.9M | 2025-Q3 |
| FMR LLC | DOUBLED | 3,635 | 35,094 | +865.4% | $3.2M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 78,635 | 18,253 | -76.8% | $1.7M | 2025-Q3 |
| NORGES BANK | EXIT | 9,585 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | ADD | 264,390 | 404,702 | +53.1% | $26.4M | 2025-Q2 |
| MORGAN STANLEY | TRIM | 437,453 | 200,876 | -54.1% | $13.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 140,549 | 185,465 | +32.0% | $12.1M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 219,502 | 128,387 | -41.5% | $8.4M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 9,779 | 78,635 | +704.1% | $5.1M | 2025-Q2 |
| NORGES BANK | NEW | — | 9,585 | — | $625.4K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 14,079 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | ADD | 226,578 | 437,453 | +93.1% | $29.3M | 2025-Q1 |
| UBS Group AG | TRIM | 594,810 | 264,390 | -55.6% | $17.7M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 14,079 | — | $942.6K | 2025-Q1 |
| UBS Group AG | DOUBLED | 286,488 | 594,810 | +107.6% | $32.9M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 401,329 | 226,578 | -43.5% | $12.5M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 245,102 | 175,800 | -28.3% | $9.7M | 2024-Q4 |
10 unique insiders with 20 transactions. Net insider value: -$8.6M ($0.00 bought, $8.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $78.16 | $39.1K |
| May 13, 2026 | Walsh Patrick D | Director | SELL | 10,000 | $80.63 | $806.3K |
| May 12, 2026 | Gutwerg Ori | SVP, GENERICS | SELL | 2,772 | $79.50 | $220.4K |
| May 12, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | SELL | 459 | $79.21 | $36.4K |
| May 11, 2026 | Lalwani Nikhil | PRESIDENT & CEO | SELL | 55,000 | $77.57 | $4.3M |
| May 11, 2026 | Walsh Patrick D | Director | SELL | 3,973 | $80.75 | $320.8K |
| Apr 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $77.95 | $39.0K |
| Mar 13, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | SELL | 3,162 | $71.64 | $226.5K |
| Mar 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $72.62 | $36.3K |
| Mar 11, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | SELL | 4,772 | $74.91 | $357.5K |
| Mar 9, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | SELL | 5,087 | $74.13 | $377.1K |
| Mar 9, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | SELL | 3,602 | $74.18 | $267.2K |
| Mar 7, 2026 | CAREY STEPHEN P. | SVP & CFO | F | 5,150 | $74.04 | $381.3K |
| Mar 7, 2026 | Lalwani Nikhil | PRESIDENT & CEO | F | 17,060 | $74.04 | $1.3M |
| Mar 7, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | F | 3,314 | $74.04 | $245.4K |
| Mar 7, 2026 | Gutwerg Ori | SVP, GENERICS | F | 3,314 | $74.04 | $245.4K |
| Mar 6, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | SELL | 2,121 | $74.22 | $157.4K |
| Mar 6, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | SELL | 1,485 | $75.00 | $111.4K |
| Mar 3, 2026 | Walsh Patrick D | Director | SELL | 6,000 | $74.23 | $445.4K |
| Mar 3, 2026 | Gutwerg Ori | SVP, GENERICS | SELL | 2,060 | $76.50 | $157.6K |
| Feb 28, 2026 | CAREY STEPHEN P. | SVP & CFO | F | 2,773 | $73.90 | $204.9K |
| Feb 28, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | F | 1,555 | $73.90 | $114.9K |
| Feb 28, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | F | 1,555 | $73.90 | $114.9K |
| Feb 28, 2026 | Lalwani Nikhil | PRESIDENT & CEO | F | 12,217 | $73.90 | $902.8K |
| Feb 28, 2026 | Gutwerg Ori | SVP, GENERICS | F | 2,221 | $73.90 | $164.1K |
| Feb 28, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | F | 628 | $73.90 | $46.4K |
| Feb 28, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | F | 2,221 | $73.90 | $164.1K |
| Feb 28, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | F | 2,221 | $73.90 | $164.1K |
| Feb 26, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | A | 13,895 | $77.15 | $1.1M |
| Feb 26, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | A | 11,116 | $77.15 | $857.6K |
| Feb 26, 2026 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | A | 11,116 | $77.15 | $857.6K |
| Feb 26, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | A | 21,306 | $77.15 | $1.6M |
| Feb 26, 2026 | Lalwani Nikhil | PRESIDENT & CEO | A | 75,592 | $77.15 | $5.8M |
| Feb 26, 2026 | CAREY STEPHEN P. | SVP & CFO | A | 22,233 | $77.15 | $1.7M |
| Feb 26, 2026 | Gutwerg Ori | SVP, GENERICS | A | 12,969 | $77.15 | $1.0M |
| Feb 26, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | A | 6,021 | $77.15 | $464.5K |
| Feb 26, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | A | 10,810 | $77.15 | $834.0K |
| Feb 20, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | SELL | 1,730 | $77.99 | $134.9K |
| Feb 20, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | SELL | 5,323 | $78.02 | $415.3K |
| Feb 19, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | SELL | 2,084 | $77.53 | $161.6K |
| Feb 14, 2026 | CAREY STEPHEN P. | SVP & CFO | F | 2,448 | $77.36 | $189.4K |
| Feb 14, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | F | 2,403 | $77.36 | $185.9K |
| Feb 14, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | F | 1,717 | $77.36 | $132.8K |
| Feb 14, 2026 | Gutwerg Ori | SVP, GENERICS | F | 1,888 | $77.36 | $146.1K |
| Feb 14, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | F | 1,779 | $77.36 | $137.6K |
| Feb 14, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | F | 485 | $77.36 | $37.5K |
| Feb 14, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | F | 1,290 | $77.36 | $99.8K |
| Feb 14, 2026 | Lalwani Nikhil | PRESIDENT & CEO | F | 10,298 | $77.36 | $796.7K |
| Feb 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $76.80 | $38.4K |
| Feb 12, 2026 | CAREY STEPHEN P. | SVP & CFO | F | 2,829 | $76.70 | $217.0K |
9 SEC filing reports analyzed. Sentiment: 3 bullish, 1 bearish, 0 mixed, 5 neutral. Avg impact: 5.3/10.
NEUTRAL
CLUSTER
4/10
A cluster of insider sales at ANI Pharmaceuticals, led by CEO Nikhil Lalwani selling $4.27M worth of
May 14, 2026
BULLISH
8-K
7/10
ANI Pharmaceuticals published an updated May 2026 investor presentation via an 8-K (Item 7.01), reit
May 13, 2026
BULLISH
8-K
8/10
ANI Pharmaceuticals reported Q1 2026 revenue of $237.5M (+20.5% YoY) and GAAP diluted EPS of $1.28,
May 8, 2026
BULLISH
PRESS-RELEASE
8/10
ANI Pharmaceuticals reported Q1 2026 adjusted non-GAAP diluted EPS of $2.05, beating the $1.30 conse
May 8, 2026
NEUTRAL
PRESS-RELEASE
3/10
ANI Pharmaceuticals announced it will release its Q1 2026 financial results on May 8, 2026. No finan
Apr 24, 2026
NEUTRAL
8-K
4/10
ANI Pharmaceuticals dismissed EisnerAmper as its auditor and appointed Ernst & Young effective April
Apr 7, 2026
BEARISH
CLUSTER
6/10
Seven corporate insiders at ANI Pharmaceuticals sold shares in the past week, including five open-ma
Mar 13, 2026
NEUTRAL
CLUSTER
5/10
Multiple executives at ANI Pharmaceuticals, including the CEO, CFO, and other senior leaders, engage
Mar 10, 2026
NEUTRAL
CLUSTER
3/10
ANI Pharmaceuticals CFO Stephen P. Carey surrendered 5,150 shares to cover tax obligations in connec
Mar 10, 2026
Historical analyst distribution (last covering-analyst action Jan 2026): 86% buy across 14 analysts — 5 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$109.88 mean target (Jan 2026)
$90.00 Low
$124.00 High
| Metric | Value |
|---|---|
| Current Price | $81.66 |
| Target Low | $90.00 |
| Target Mean | $109.88 |
| Target Median | $110.00 |
| Target High | $124.00 |
| # Analysts | 8 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$2.00 | $1.95 | $2.04 | 11.1% | -8.2% | 1↑ 4↓ | $0.3B | 24.8% | 7 |
| Next Q 2026-09-30 |
$2.52 | $2.28 | $2.80 | 23.3% | +0.3% | 3↑ 2↓ | $0.3B | 31.3% | 7 |
| Current FY 2026-12-31 |
$9.40 | $9.19 | $9.60 | 19.1% | +3.6% | 6↑ 0↓ | $1.1B | 27.1% | 7 |
| Next FY 2027-12-31 |
$10.61 | $9.48 | $13.06 | 12.9% | +0.2% | 2↑ 4↓ | $1.2B | 11.2% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $2.000 | |
| 7d ago | $1.998 | +0.002 |
| 30d ago | $2.178 | -0.178 |
| 60d ago | $2.177 | -0.177 |
| 90d ago | $2.078 | -0.077 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 16, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Dec 9, 2025 | Barclays | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 10, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 8, 2026
earnings
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
<p>PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results
May 8, 2026
earnings_calendar
ANIP Q1 2026 Earnings Scheduled — 2026-05-08
Apr 24, 2026
earnings
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
<p>PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Compan
Apr 20, 2026
fda
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
<p align="justify">PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced
Apr 14, 2026
FDA
Duloxetine
BOXED WARNING WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents,
Apr 13, 2026
other
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
<p align="justify">PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced
Apr 13, 2026
FDA
Carbamazepine
WARNING SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS
Apr 8, 2026
fda
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
<p align="justify">PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced
Apr 7, 2026
fda
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
<p>PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of
Feb 27, 2026
earnings_calendar
ANIP Q4 2025 Earnings After Market Close — 2026-02-27